Q2 2021 Results - Reimagining Medicine
Participants
Company overview
Pharmaceuticals
Oncology
Financial review
Conclusion
Appendix
References
1
GROWTH
Key growth drivers and launches continued momentum in Q2
Q2 key growth driver sales momentum¹
Sales
USD Million
Entresto
886
Growth vs. PY
Growth vs. PY
USD Million
CC
Key growth drivers and launches
306
46%
Driving portfolio rejuvenation
51% of IM sales, growing 29% in Q2
sacubitillvalsartan
Cosentyx
1,175
231
21%
(secukinumab)
zolgensma 315
110
48%
PROMACTA
513
91
18%
(eltrombopag
43%
JAKAVI
398
88
19%
ruxolitinib
AimovigⓇ
KesimptaⓇ
51%
MayzentⓇ
PiqrayⓇ
XiidraⓇ
LutatheraⓇ
KymriahⓇ
33%
Xolair
355
66
14%
KisqaliⓇ
Omalizumab
KISQALI
225
66
36%
25%
llarisⓇ
ribociclib
Kesimpta
66
66
nm
(ofatumumab)
Tafinlar. Mekinist
425
54
ILARIS
(canakinumab)
247
47
Xiidra
118
39
69
35
10%
21%
48%
96%
ZolgensmaⓇ
JakaviⓇ
Tafinlar+MekinistⓇ
PromactaⓇ
EntrestoⓇ
MAYZENT.
(siponimod) tablets
nm not meaningful
1. Innovative Medicines division. Constant currencies (cc) is a non-IFRS measure; explanation of non-IFRS measures can be found on page 48 of Condensed Interim Financial Report. Unless otherwise noted, all growth rates refer to same
period in PY
Cosentyx®
Q2 2018
Q2 2019
Q2 2020
*Includes XolairⓇ, BeovuⓇ, Adakveo®, Luxturna®, TabrectaⓇ,
Enerzair, AtecturaⓇ and LeqvioⓇ
Q2 2021
Other
7 Investor Relations | Q2 2021 Results
✓ NOVARTIS | Reimagining MedicineView entire presentation